FDA Accepts Revance Resubmission for Frown Line Treatment
The FDA has accepted Revance's BLA resubmission for DaxibotulinumtoxinA for Injection, designed to treat severe glabellar lines.
The FDA has accepted Revance's BLA resubmission for DaxibotulinumtoxinA for Injection, designed to treat severe glabellar lines.
The American Society of Plastic Surgeons (ASPS) has released supplemental data for its 2022 procedural statistics, revealing generational trends, increasing male interest in minimally invasive procedures, and fluctuating surgeon fees, with an emphasis on safety and authenticity in the pursuit of beauty and self-confidence.